

## Renin-Angiotensin System in HPMC : Implication for Peritoneal Fibrosis and Hyperpermeability

Hyunjin Noh, M.D., Hunjoo Ha, M.D.<sup>\*</sup>, Mi Ra Yu, M.D.  
Young Ok Kim, M.D., Ji Hye Kim, M.D.<sup>†</sup>, Hi Bahl Lee, M.D.

*Hyonam Kidney Laboratory, Soon Chun Hyang University,  
Ewha Womans University College of Pharmacy,  
BK21 Project for Medical Sciences Yonsei University<sup>†</sup>, Korea*

**Background :** Angiotensin (Ang) II plays an important role in renal fibrosis in diabetes and may similarly promote peritoneal fibrosis during long-term peritoneal dialysis (PD) using glucose-based PD solutions. It is not known, however, if human peritoneal mesothelial cells (HPMC) express renin-angiotensin system (RAS).

**Methods :** In cultured HPMC, the expression of mRNAs for angiotensinogen, angiotensin-converting enzyme (ACE), Ang II receptor type 1 (AT1), and transforming growth factor (TGF)- $\beta$ 1 was evaluated by real-time PCR, ACE, AT1, and vascular endothelial growth factor (VEGF) proteins by Western blot analysis, and Ang I, Ang II, and TGF- $\beta$ 1 proteins by ELISA. We also measured Ang II, TGF- $\beta$ 1, and VEGF proteins in overnight PD effluent from 22 PD patients with or without ultrafiltration failure (UFF).

**Results :** HPMC constitutively expressed all the components of RAS. 50 mM D-glucose (high glucose : HG) significantly increased expression of angiotensinogen, ACE, and AT1 mRNAs. HG upregulated ACE, AT1, and Ang II proteins. Ang II increased TGF- $\beta$ 1 and VEGF expression. Losartan prevented HG-induced upregulation of TGF- $\beta$ 1. Effluent Ang II and TGF- $\beta$ 1 protein concentrations were significantly higher in patients with UFF and significant correlations were found among effluent Ang II, TGF- $\beta$ 1, and VEGF and between dialysate to plasma creatinine ratio and concentrations of Ang II, TGF- $\beta$ 1, or VEGF in PD effluent.

**Conclusion :** These data demonstrate that HPMC constitutively express all components of RAS and suggest that locally produced Ang II by HPMC may be a potential therapeutic target in peritoneal fibrosis and hyperpermeability during long-term PD.